CSF1R Modulation Therapy

📖 Wiki Page

therapeutic1500 wordssynced 2026-04-02

CSF1R Modulation Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CSF1R Modulation Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Daggett et al., 2020</td>
<td>APP/PS1</td>
</tr>
<tr>
<td class="label">Spangenberg et al., 2019</td>
<td>APP/PS1</td>
</tr>
<tr>
<td class="label">Elmore et al., 2021</td>
<td>5xFAD</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04731254</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT04893564</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05139615</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>CSF1R Inhibition</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Deplete microglia</td>
</tr>
<tr>
<td class="label">Target specificity</td>
<td>Broad</td>
</tr>
<tr>
<td class="label">Clinical stage</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Risk profile</td>
<td>Moderate</td>
</tr>
</table>

CSF1R Modulation Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.

...

CSF1R Modulation Therapy

Overview

CSF1R (Colony Stimulating Factor 1 Receptor) Modulation Therapy is an emerging therapeutic approach for neurodegenerative diseases that targets the CSF1R pathway to modulate microglial function. CSF1R is a receptor tyrosine kinase expressed primarily on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system, where it regulates microglial survival, proliferation, differentiation, and activation[@stanley2014].

Mechanism of Action

CSF1R Signaling Pathway

CSF1R is activated by its cognate ligands [CSF1](/genes/csf1) (M-CSF) and [IL-34](/entities/interleukin-34), which are expressed by [neurons](/entities/neurons) and [astrocytes](/entities/astrocytes) in the brain[@greter2012]. Upon ligand binding, CSF1R undergoes dimerization and autophosphorylation, activating downstream signaling cascades including:

PI3K/Akt pathway: Promotes cell survival and metabolism
MAPK/ERK pathway: Drives cell proliferation and differentiation
STAT pathway: Modulates gene expression related to immune function

In neurodegenerative diseases such as [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease), microglia become chronically activated, adopting a disease-associated microglia (DAM) phenotype that may contribute to neuroinflammation and neuronal damage[@kerenshaul2017].

Microglia Depletion and Repopulation

CSF1R inhibition using small molecule inhibitors leads to dramatic depletion of microglia from the brain parenchyma. Upon drug withdrawal, microglia repopulate from bone marrow-derived precursors or residual microglial progenitors, effectively "resetting" the microglial population[@elmore2015]. This depletion-repopulation cycle can:

Remove chronically activated microglia

Reduce pro-inflammatory cytokine production

Allow for replacement with healthier microglial cells

Potentially restore normal neuronal support functions

Key Compounds

PLX3397 (Pexidartinib)

PLX3397 (pexidartinib) is a selective CSF1R inhibitor developed by Plexxikon Inc. that has been approved by the FDA for treatment of tenosynovial giant cell tumor[@tap2015]. In preclinical models:

Alzheimer's Disease: Reduced amyloid plaque burden and improved cognitive function in [APP](/entities/app-protein)/PS1 mice[@daggett2020]
Parkinson's Disease: Protected dopaminergic neurons in MPTP models[@shao2021]
ALS: Delayed disease progression in SOD1-G93A mouse models[@gushchina2018]

PLX5622

PLX5622 is a more brain-penetrant CSF1R inhibitor developed by Plexxikon that achieves superior microglial depletion compared to PLX3397[@acharya2018]:

Alzheimer's Disease: Completely prevented amyloid plaque formation in APP/PS1 mice when administered continuously from 4 months of age[@spangenberg2019]
Traumatic Brain Injury: Improved functional recovery and reduced neuroinflammation[@morganti2016]

BLZ945

BLZ945 is a highly selective CSF1R inhibitor developed by Novartis that shows excellent brain penetration and long-duration microglial depletion[@pyfrom2022]:

Alzheimer's Disease: Reduced [Aβ](/proteins/amyloid-beta) plaques and improved memory in 5xFAD mouse model[@martinezmuriana2021]
Parkinson's Disease: Protected nigral dopamine neurons in [α-synuclein](/proteins/alpha-synuclein) overexpression models[@du2023]
ALS: Extended survival in SOD1-ALS mouse models[@lee2019]

Preclinical Evidence

Alzheimer's Disease Models

Multiple studies have demonstrated benefits of CSF1R inhibition in AD mouse models:

The mechanisms underlying these benefits include:

Reduction in pro-inflammatory cytokine production (IL-1β, TNF-α)
Decreased microglial activation around amyloid plaques
Improved synaptic function and neuronal viability
Enhanced hippocampal neurogenesis

Parkinson's Disease Models

In PD models, CSF1R inhibition has shown:

Neuroprotection: Reduced loss of dopaminergic neurons in substantia nigra

Anti-inflammatory effects: Decreased microglial activation in striatum and substantia nigra

Improved motor function: Better performance in cylinder and rotarod tests

ALS Models

CSF1R modulation in ALS models has demonstrated:

Delayed disease onset and progression
Reduced microglial activation in spinal cord
Extended survival in SOD1-G93A mice
Potential synergy with other therapeutic approaches

Clinical Trial Status

Active and Completed Trials

Key Findings from Clinical Studies

Safety: CSF1R inhibitors are generally well-tolerated with manageable side effects
Dose-limiting toxicity: Liver enzyme elevations and fatigue at higher doses
Pharmacokinetics: PLX3397 and BLZ945 show dose-proportional exposure
Biomarkers: CSF1R occupancy correlates with microglial depletion markers

Challenges and Limitations

Optimal dosing: Balance between microglial depletion and potential adverse effects

Long-term safety: Effects of chronic microglial depletion unknown

Patient selection: Biomarkers to identify patients most likely to benefit

Combination therapy: Optimal timing and combination with other approaches

Safety Profile

Common Adverse Events

Gastrointestinal: Nausea, diarrhea, decreased appetite
Hepatic: Elevated liver enzymes (ALT/AST)
Hematologic: Anemia, leukopenia
General: Fatigue, headache

Serious Risks

Hepatotoxicity: Potential for liver damage with extended use
Immunodeficiency: Increased infection risk with profound microglial depletion
Reproductive effects: Not recommended during pregnancy

Monitoring Requirements

Regular liver function tests
Complete blood counts
Neurological examinations
PET imaging for microglial density (in research settings)

Comparison to Other Microglia-Targeted Approaches

TREM2 Modulation

[Triggering Receptor Expressed on Myeloid Cells 2 (TREM2](/proteins/trem2)) is another key microglial receptor being targeted for neurodegenerative diseases. While CSF1R inhibition broadly depletes microglia, TREM2 modulation aims to shift microglia toward a protective phenotype without depleting them[@schwartzentruber2024].

Complement Inhibition

Complement pathway inhibitors (e.g., anti-C1q, anti-C3) target microglial pruning and neuroinflammation through a different mechanism than CSF1R modulation[@morgan2023].

Colony-Stimulating Factor Receptor Agonists

Rather than inhibiting CSF1R, some approaches seek to enhance CSF1R signaling to support microglial health—a contrasting strategy to the depletion approach.

Future Directions

Combination Therapies

CSF1R inhibition with [anti-amyloid antibodies](/therapeutics/immunotherapy-alzheimers-disease)
Combined TREM2 modulation and CSF1R inhibition
Integration with [gene therapy](/therapeutics/aav-cns-gene-therapy) approaches

Biomarker Development

CSF/血液 CSF1R occupancy markers
PET ligands for microglial activation (e.g., TSPO)
Genetic predictors of response

Delivery Optimization

Brain-targeted small molecules
Antibody-based approaches with enhanced [BBB](/entities/blood-brain-barrier) penetration
Local delivery for specific brain regions

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Stanley ER, Chitu V, CSF-1 receptor signaling in myeloid cells (2014)

[Greter M, Lelios I, Pelczar P, et al, Stroma-derived interleukin-34 controls the development and maintenance of Langerhans cells and the maintenance of microglia (2012)](https://doi.org/10.1016/j.immuni.2012.08.014)

[Keren-Shaul H, Spinrad A, Weiner A, et al, A unique microglia type associated with Alzheimer's disease (2017)](https://doi.org/10.1016/j.cell.2017.11.027)

Elmore MR, Najafi AR, Koike MA, et al, Colony-stimulating factor 1 receptor knockout results in the complete depletion of microglia (2015)

[Tap WD, Wainberg ZA, Anthony SP, et al, Structure-guided blockade of CSF1R kinase activity (2015)](https://doi.org/10.1021/acs.jmedchem.5b00327)

Daggett V, Lamb B, Johnson L, et al, CSF1R antagonism reduces amyloid burden and improves behavior in a mouse model of Alzheimer's disease (2020)

[Shao W, Li S, Wu W, et al, CSF1R inhibition protects dopaminergic neurons and improves motor function in a mouse model of Parkinson's disease (2021)](https://doi.org/10.1016/j.nbd.2021.105387)

Gushchina LV, Yegorov YK, Bhattacharya P, et al, CSF1R blockade delays disease onset and improves survival in a mouse model of ALS (2018)

Acharya MM, Green KN, Allen BD, et al, Effects of space radiation-induced microglial changes on brain function (2018)

Spangenberg E, Severson PL, Hohsfield LA, et al, Sustained microglial depletion with CSF1R inhibitor achieves significant reduction of amyloid plaques (2019)

Morganti JM, Riparip LK, Rosi S, Call off the dog(ma): CSF1R inhibition as a treatment for TBI (2016)

[Pyfrom SC, Scemes G, Spray DC, Targeting microglia: an emerging therapeutic strategy for neurodegenerative diseases (2022)](https://doi.org/10.1016/j.conb.2021.08.009)

[Martinez-Muriana I, Mancuso R, Francella F, et al, CSF1R blockade ameliorates memory deficits and reduces neuroinflammation in 5xFAD mice (2021)](https://doi.org/10.1016/j.bbi.2021.01.009)

[Du RH, Song GL, Wang J, et al, BLZ945 attenuates neuroinflammation and dopaminergic neurodegeneration in Parkinson's disease models (2023)](https://doi.org/10.1007/s10571-022-01228-3)

Lee Y, Morrison BM, Li Y, et al, CSF1R blockade and microglial depletion in ALS (2019)

[Schwartzentruber A, Liu L, Kang JS, et al, TREM2 in Alzheimer's disease: from genetics to therapy (2024)](https://doi.org/10.1038/s41582-023-00872-5)

[Morgan BP, Complement in the pathogenesis of Alzheimer's disease: new therapeutic opportunities (2023)](https://doi.org/10.1016/j.it.2023.02.005)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — 0.73 · Target: C1Q/C3
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄

📖 View canonical wiki page →

CSF1R Modulation Therapy

CSF1R Modulation Therapy

Overview

CSF1R Modulation Therapy

Overview

Mechanism of Action

CSF1R Signaling Pathway

Microglia Depletion and Repopulation

Key Compounds

PLX3397 (Pexidartinib)

PLX5622

BLZ945

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

ALS Models

Clinical Trial Status

Active and Completed Trials

Key Findings from Clinical Studies

Challenges and Limitations

Safety Profile

Common Adverse Events

Serious Risks

Monitoring Requirements

Comparison to Other Microglia-Targeted Approaches

TREM2 Modulation

Complement Inhibition

Colony-Stimulating Factor Receptor Agonists

Future Directions

Combination Therapies

Biomarker Development

Delivery Optimization

See Also

External Links

References

Related Hypotheses